Astrazeneca (AZN) Consolidated Net Income (2009 - 2026)

Astrazeneca's Consolidated Net Income history runs 18 years deep, the most recent figure standing at $3.9 billion for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 15.05% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $12.9 billion (up 38.96% YoY), while the FY2025 annual figure was $10.2 billion, up 45.33% from the prior year.
• Consolidated Net Income was $3.9 billion for Q1 2026 at Astrazeneca, up from $2.6 billion in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $3.9 billion in Q1 2026 to a low of $247.0 million in Q2 2022.
• Historically, Consolidated Net Income has averaged $2.0 billion across 5 years, with a median of $2.1 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Consolidated Net Income slumped 67.67% in 2022, then surged 745.34% in 2023.
• A 5-year view of Consolidated Net Income shows it stood at $778.0 million in 2022, then grew by 15.3% to $897.0 million in 2023, then soared by 85.73% to $1.7 billion in 2024, then surged by 57.8% to $2.6 billion in 2025, then soared by 48.88% to $3.9 billion in 2026.
• The last three Consolidated Net Income figures came in at $3.9 billion (Q1 2026), $2.6 billion (Q4 2025), and $3.2 billion (Q3 2025), per Business Quant data.